The document reviews various hair and naildisorders, their causes, and treatments, emphasizing the need for proper diagnosis and the link between nail changes and systemic diseases.
This review discusses various adverse drug reactions affecting the skin, hair, and nails, emphasizing the importance of recognizing and reporting these reactions but reports no new clinical findings.
This article reviews drug-induced hair and naildisorders and discusses their clinical recognition, underlying mechanisms, and potential treatment strategies, without presenting new research findings.
Oral biotin combined with topical minoxidil may increase hair growth rate, though the study was limited to healthy subjects and did not measure hair density. Some users report personal benefits from biotin, such as faster nail growth and healthier hair, but concerns about acne and study quality were also mentioned.
A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
A user is experiencing rapid hair loss and has been diagnosed with telogen effluvium by multiple dermatologists, but doubts the diagnosis due to the severity and speed of the hair loss. They are considering various treatments like spironolactone, estradiol, and possibly finasteride, while also exploring the possibility of hormonal imbalances or autoimmune issues.
Vitamin D deficiency can contribute to hair loss, but it is not the sole cause, and supplementation may not always resolve the issue. Treatments like finasteride and minoxidil are recommended for hair regrowth, with vitamin D and other supplements providing additional support.
An 18-year-old with early hair loss is advised to consider minoxidil and finasteride, with a doctor's consultation recommended. Alternatives like a hair system or shaving are suggested due to potential medication side effects and lifelong commitment.